Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henry J Henk

Showing results (11-20 of 45) with videos related to

Pageof 5
Sort By:
The Oncologist|January 10, 2013
Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims dataApril Teitelbaum, Abbie Ba-Mancini, Hui Huang, et al.
Journal of the National Cancer Institute. Monographs|July 5, 2022
Methods and Study Design for Cancer Health Economics Research: Summary of Discussions From a Breakout SessionHenry J Henk, Ya-Chen Tina Shih, Bijan J Borah
American Journal of Hematology|March 29, 2012
Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myelomaHenry J Henk, April Teitelbaum, Jose Ricardo Perez, et al.
Current Medical Research and Opinion|February 28, 2012
Patient survival and healthcare utilization costs after diagnosis of triple-negative breast cancer in a United States managed care cancer registryOnur Baser, Wenhui Wei, Henry J Henk, et al.
Clinicoeconomics and Outcomes Research : CEOR|July 23, 2013
Retrospective claims analysis of best supportive care costs and survival in a US metastatic renal cell populationHenry J Henk, Connie Chen, Agnes Benedict, et al.
Journal of Lower Genital Tract Disease|December 31, 2009
Incidence and costs of cervical intraepithelial neoplasia in a US commercially insured populationHenry J Henk, Ralph P Insinga, Puneet K Singhal, et al.
Current Medical Research and Opinion|October 31, 2014
Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world settingErin K Buysman, Wing Chow, Henry J Henk, et al.
BMC Endocrine Disorders|November 4, 2015
Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysisErin K Buysman, Wing Chow, Henry J Henk, et al.
Current Medical Research and Opinion|September 29, 2015
Canagliflozin treatment of Hispanic and non-Hispanic patients with type 2 diabetes in a US managed care settingWing Chow, Erin Buysman, Marcia F T Rupnow, et al.
Clinical and Experimental Gastroenterology|June 23, 2011
Mortality associated with gastrointestinal bleeding events: Comparing short-term clinical outcomes of patients hospitalized for upper GI bleeding and acute myocardial infarction in a US managed care settingC Mel Wilcox, Byron L Cryer, Henry J Henk, et al.
Pageof 5

Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
The Oncologist|January 10, 2013
Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims dataApril Teitelbaum, Abbie Ba-Mancini, Hui Huang, et al.
Journal of the National Cancer Institute. Monographs|July 5, 2022
Methods and Study Design for Cancer Health Economics Research: Summary of Discussions From a Breakout SessionHenry J Henk, Ya-Chen Tina Shih, Bijan J Borah
American Journal of Hematology|March 29, 2012
Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myelomaHenry J Henk, April Teitelbaum, Jose Ricardo Perez, et al.
Current Medical Research and Opinion|February 28, 2012
Patient survival and healthcare utilization costs after diagnosis of triple-negative breast cancer in a United States managed care cancer registryOnur Baser, Wenhui Wei, Henry J Henk, et al.
Clinicoeconomics and Outcomes Research : CEOR|July 23, 2013
Retrospective claims analysis of best supportive care costs and survival in a US metastatic renal cell populationHenry J Henk, Connie Chen, Agnes Benedict, et al.
Journal of Lower Genital Tract Disease|December 31, 2009
Incidence and costs of cervical intraepithelial neoplasia in a US commercially insured populationHenry J Henk, Ralph P Insinga, Puneet K Singhal, et al.
Current Medical Research and Opinion|October 31, 2014
Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world settingErin K Buysman, Wing Chow, Henry J Henk, et al.
BMC Endocrine Disorders|November 4, 2015
Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysisErin K Buysman, Wing Chow, Henry J Henk, et al.
Current Medical Research and Opinion|September 29, 2015
Canagliflozin treatment of Hispanic and non-Hispanic patients with type 2 diabetes in a US managed care settingWing Chow, Erin Buysman, Marcia F T Rupnow, et al.
Clinical and Experimental Gastroenterology|June 23, 2011
Mortality associated with gastrointestinal bleeding events: Comparing short-term clinical outcomes of patients hospitalized for upper GI bleeding and acute myocardial infarction in a US managed care settingC Mel Wilcox, Byron L Cryer, Henry J Henk, et al.
Pageof 5